Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

We would like to congratulate Tariq Khoyratty, who has been appointed as a Celgene Fellow to study the link between neutrophil chromatin organisation in rheumatic patients and their ability to form pathogenic extracellular traps.

Recent evidence suggests an essential contribution of neutrophils in immunity, inflammation and cancer that extend far beyond their well-known anti-microbial responses. This evidence includes their ability to release extracellular DNA structures. The release of extracellular DNA leads to externalizing enhanced levels of putative autoantigens, and is considered to be particularly relevant to neutrophil deleterious roles in rheumatic diseases. This phenomenon is currently collectively referred to as neutrophil extracellular trap (NET) formation.

PAD4 is an enzyme capable of citrullinating proteins that is being considered as an interesting therapeutic target in rheumatic disorders. The primary interest is to determine whether PAD4 inhibition impacts NET formation in human neutrophils in response to disease-relevant stimuli and to determine whether sub-populations of patients are more prone to citrullination-associated NETosis and thus more likely to respond to a PAD4 inhibitor. Mechanistically, NET formation has been linked to a programmed genome disassembly that is precisely organised and sequence programmed at the level of chromatin organisation.

Speaking of the award, Tariq commented “Ultimately, our aim is to define an early signature in peripheral neutrophils that would correlate with disease severity and propensity to form NETs and can easily be detected in human serum or blood.”

Tariq will be based primarily in the Kennedy Institute and work under the supervision of Prof Irina Udalova and Raashid Luqmani

The fellowship starts in November 2017 and runs for 36 months.

Similar stories

NDORMS researchers awarded for Dupuytren research

Awards Hand Kennedy Main

Three NDORMS researchers have received awards from the International Dupuytren Society, a patient organisation that brings together Dupuytren Disease patient societies from across the world.

Hope for rheumatoid arthritis patients who are non-responsive to anti-TNF

Arthritis Kennedy Main

New research published in The Lancet shows that tocilizumab is a more effective treatment than rituximab for rheumatoid arthritis patients with a poor response to anti-tumour necrosis factor (TNF).

A new study maps the expression of innate immune receptors during the course of arthritis

Arthritis Kennedy Main

The research, which was a collaboration with researchers from Oxford University and Queen Mary University of London and published in Journal of Autoimmunity, looked at changes in receptors known as toll-like receptors (TLRs) in arthritis at different stages of disease.

International Women's Day

Department Main

It’s International Women's Day! This year’s theme is #Choosetochallenge. We’re celebrating some of the amazing women at NDORMS, and asking them what changes they’d like to see in medical sciences over the next 100 years.

Patients and carers invited to join new group helping to shape research and treatment of bones, muscles and joints

Main PPI

Oxford’s newest patient partner group, OPEN ARMS launches today to explore the causes, treatment and care for patients with musculoskeletal conditions. Its first three patient partners explain why they are involved and invite other members of the public to join the team.

NDORMS academics named NIHR Senior Investigators

Main

Congratulations to Professor Jonathan Rees who has been announced as a National Institute of Health Research (NIHR Senior Investigator).